|
Name |
(Z)-beta-Ocimene epoxide
|
Molecular Formula | C10H16O | |
IUPAC Name* |
2,2-dimethyl-3-[(2Z)-3-methylpenta-2,4-dienyl]oxirane
|
|
SMILES |
C/C(=C/CC1C(O1)(C)C)/C=C
|
|
InChI |
InChI=1S/C10H16O/c1-5-8(2)6-7-9-10(3,4)11-9/h5-6,9H,1,7H2,2-4H3/b8-6-
|
|
InChIKey |
LIMXJCIGROLRED-VURMDHGXSA-N
|
|
Synonyms |
cis-Myroxide; (Z)-Myroxide; (Z)-beta-Ocimene epoxide; (Z)-6,7-Epoxyocimene; (Z)-.beta.-Ocimene epoxide; 4L6651QT3T; 1,3-Octadiene, 6,7-epoxy-3,7-dimethyl-, (Z)-; 33281-83-3; 2,2-Dimethyl-3-((2Z)-3-methyl-2,4-pentadien-1-yl)oxirane; Oxirane, 2,2-dimethyl-3-((2Z)-3-methyl-2,4-pentadien-1-yl)-; beta-Ocimene epoxide, (Z)-; Oxirane, 2,2-dimethyl-3-[(2Z)-3-methyl-2,4-pentadien-1-yl]-; UNII-4L6651QT3T; .BETA.-OCIMENE EPOXIDE, (Z)-; Q27896140; (Z)-2,2-Dimethyl-3-(3-methylpenta-2,4-dien-1-yl)oxirane; Oxirane, 2,2-dimethyl-3-(3-methyl-2,4-pentadienyl)-, (Z)-; Oxirane, 2,2-dimethyl-3-[(2Z)-3-methyl-2,4-pentadienyl]-
|
|
CAS | 33281-83-3 | |
PubChem CID | 14701631 | |
ChEMBL ID | NA |
Chemical Classification: |
|
|
---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
---|---|---|---|---|---|---|---|---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
Molecular Weight: | 152.23 | ALogp: | 2.9 |
HBD: | 0 | HBA: | 1 |
Rotatable Bonds: | 3 | Lipinski's rule of five: | Accepted |
Polar Surface Area: | 12.5 | Aromatic Rings: | 1 |
Heavy Atoms: | 11 | QED Weighted: | 0.445 |
Caco-2 Permeability: | -4.272 | MDCK Permeability: | 0.00002500 |
Pgp-inhibitor: | 0 | Pgp-substrate: | 0 |
Human Intestinal Absorption (HIA): | 0.003 | 20% Bioavailability (F20%): | 0.002 |
30% Bioavailability (F30%): | 0.005 |
Blood-Brain-Barrier Penetration (BBB): | 0.925 | Plasma Protein Binding (PPB): | 81.92% |
Volume Distribution (VD): | 1.543 | Fu: | 9.72% |
CYP1A2-inhibitor: | 0.103 | CYP1A2-substrate: | 0.16 |
CYP2C19-inhibitor: | 0.063 | CYP2C19-substrate: | 0.863 |
CYP2C9-inhibitor: | 0.023 | CYP2C9-substrate: | 0.068 |
CYP2D6-inhibitor: | 0.008 | CYP2D6-substrate: | 0.302 |
CYP3A4-inhibitor: | 0.042 | CYP3A4-substrate: | 0.375 |
Clearance (CL): | 10.689 | Half-life (T1/2): | 0.562 |
hERG Blockers: | 0.015 | Human Hepatotoxicity (H-HT): | 0.502 |
Drug-inuced Liver Injury (DILI): | 0.108 | AMES Toxicity: | 0.09 |
Rat Oral Acute Toxicity: | 0.05 | Maximum Recommended Daily Dose: | 0.373 |
Skin Sensitization: | 0.31 | Carcinogencity: | 0.858 |
Eye Corrosion: | 0.923 | Eye Irritation: | 0.977 |
Respiratory Toxicity: | 0.965 |
Similar NPs | Similar Drugs | ||||||
---|---|---|---|---|---|---|---|
NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
ENC000526 | 0.385 | D0H6VY | 0.280 | ||||
ENC001568 | 0.385 | D0S7WX | 0.181 | ||||
ENC003102 | 0.333 | D0M1PQ | 0.174 | ||||
ENC000847 | 0.308 | D0FG6M | 0.167 | ||||
ENC001735 | 0.302 | D0U4VT | 0.152 | ||||
ENC001734 | 0.302 | D0W6DG | 0.147 | ||||
ENC004455 | 0.297 | D02DGU | 0.145 | ||||
ENC001664 | 0.283 | D0G3PI | 0.145 | ||||
ENC001564 | 0.283 | D00DKK | 0.145 | ||||
ENC001566 | 0.268 | D09JBP | 0.143 |